Abstract: A system may generate a prompt based in part on a search query from a customer client device. The prompt instructs a machine learned model to provide item predictions. And the model was trained by: converting structured data describing items of an online catalog to annotated text data (unstructured data), generating training examples based in part on the annotated text data, and training the model using the training examples. The system may receive item predictions generated by the prompt being applied to the machine learned model, the item predictions may have corresponding item identifiers. The item predictions are processed to identify a recommended item from the item predictions. The processing includes determining item information for the recommended item using an item identifier associated with the recommended item. The item information is provided to the customer client device.

Abstract: A cleaning system may include a vacuum cleaner and a docking station. The vacuum cleaner may include an air inlet, a suction motor having a suction motor inlet and a suction motor outlet, and a cleaner dust cup configured to transition between a collection position and an emptying position, the cleaner dust cup being upstream of the suction motor inlet when in the collection position and downstream of the suction motor outlet when in the emptying position. The docking station may include a base, a support extending from the base, a station dust cup removably coupled to the support, and a receptacle coupled to the support and configured to receive at least a portion of the vacuum cleaner, the cleaner dust cup being fluidly coupled to and upstream of the station dust cup when the vacuum cleaner is inserted in the receptacle.

Abstract: A cleaning system may include a vacuum cleaner and a docking station. The vacuum cleaner may include an air inlet, a suction motor having a suction motor inlet and a suction motor outlet, and a cleaner dust cup configured to transition between a collection position and an emptying position, the cleaner dust cup being upstream of the suction motor inlet when in the collection position and downstream of the suction motor outlet when in the emptying position. The docking station may include a base, a support extending from the base, a station dust cup removably coupled to the support, and a receptacle coupled to the support and configured to receive at least a portion of the vacuum cleaner, the cleaner dust cup being fluidly coupled to and upstream of the station dust cup when the vacuum cleaner is inserted in the receptacle.

Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the disclosed compounds or compositions for treating and/or preventing diseases (e.g., inflammatory diseases, neurological diseases (e.g., Alzheimer's disease), infectious diseases (e.g., viral infections (e.g., infections caused by viral human hepatitis (e.g., hepatitis B), a flaviviridae family virus (e.g., a flavivims (e.g., Zika virus)))), and proliferative diseases (e.g., cancer (e.g., lung cancer, prostate cancer, skin cancer, thyroid cancer, pancreatic cancer, colorectal cancer, liver cancer, leukemia, or lymphoma)) in a subject. Provided are methods of inhibiting a protein kinase (e.g., MAP2K (e.g., MKK7)) in a subject. Also provided are methods of inhibiting MKK7 in a subject in need thereof.

Abstract: The present disclosure provides a data acquisition and control system of pulsed power supply for multi-load, and relates to the technical field of pulsed power. The system of the present disclosure is configured to control 18 sets of pulsed power supplies to provide 18 coils with stable and reliable excitation current featuring multiple output time sequences and flexible adjustability, such that a near-earth space plasma environment ground-based simulation device can simulate the magnetic field topology of the earth magnetosphere and realize a background magnetic field required by physical experiments. The system mainly achieves the following functions: control over charge and discharge of pulsed power supplies, selection of power supplies put in use, “delay trigger” setting, voltage monitoring, status monitoring of key components and output current display; and it is also necessary to realize failure alarm and failure handling for the purpose of ensuring the safety of equipment and personnel.

Abstract: An optimization method for an implementation of mel-frequency cepstral coefficients is provided. The optimization method includes the following steps: performing a framing step, including using a 400×16 static random access memory to temporarily store a plurality of sampling points of a sound signal with overlap, and decomposing the sound signal into a plurality of frames. Each of the plurality of frames is 400 of the sampling points, there is an overlapping region between adjacent two of the plurality of frames, and the overlapping region includes 240 of the sampling points. The optimization method further includes performing a windowing step, which includes multiplying each of the plurality of frames by a window function in a bit-level design, and the optimization method includes performing a fast Fourier transform (FFT) step, which includes applying a 512 point FFT on a frame signal to obtain a corresponding frequency spectrum.

Abstract: The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be kinase (e.g., HCK, BTK, LYN) inhibitors. Also provided are pharmaceutical compositions and kits including the provided compounds. Further provided are methods of using the provided compounds, pharmaceutical compositions, and kits (e.g., for treating diseases (e.g., proliferative diseases) in a subject in need thereof).

Abstract: The present invention provides a programmed cell necrosis inhibitor, a preparation method therefor, and a use thereof. Specifically, the present invention provides a compound, or a pharmaceutically acceptable salt, hydrate, or solvent thereof, wherein the compound is as represented by formula I. The present invention further provides a preparation method for the compound and a pharmaceutical composition containing same, or a use of the compound in treatment or prevention of diseases or disorders related to programmed cell necrosis and/or human receptor interacting protein kinase 1 (RIPK1).

Abstract: Aspects disclosed herein include an electrochemical cell comprising: an anode comprising: a first surface comprising aluminum metal or an aluminum alloy; a liquid metal on the first surface, the liquid metal being in liquid state during operation of the battery and the liquid metal having a different composition than that of the first surface; and aluminum-rich dendrites extending from the first surface and in contact with an electrolyte; a positive electrode; and the electrolyte between the positive electrode and the negative electrode, the electrolyte being capable of conducting ions.

Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the disclosed compounds or compositions for treating and/or preventing diseases (e.g., inflammatory diseases, neurological diseases (e.g., Alzheimer's disease), infectious diseases (e.g., viral infections (e.g., infections caused by viral human hepatitis (e.g., hepatitis B), a flaviviridae family virus (e.g., a flavivims (e.g., Zika virus)))), and proliferative diseases (e.g., cancer (e.g., lung cancer, prostate cancer, skin cancer, thyroid cancer, pancreatic cancer, colorectal cancer, liver cancer, leukemia, or lymphoma)) in a subject. Provided are methods of inhibiting a protein kinase (e.g., MAP2K (e.g., MKK7)) in a subject. Also provided are methods of inhibiting MKK7 in a subject in need thereof.

Abstract: This disclosure provides systems, methods and apparatuses for a high priority route selection descriptor (RSD) selection timer. A protocol data unit (PDU) session may be established for an application associated with a user equipment (UE). If the PDU session is associated with a lower RSD priority than the highest RSD priority for the application, the UE may initiate an RSD selection timer. After expiration of the RSD selection timer, the UE may try to establish another PDU session for the application with the highest RSD priority for the application. If another PDU session with the highest RSD priority is accepted, the UE may release the initial PDU session with the lower RSD priority and establish a new PDU session with the highest RSD priority. Such implementations may increase data rates, quality of service, and reliability for the application, decrease latency of the application, or decrease power consumption of the UE.

Abstract: A contact lens includes a lens body and a color ink layer. The color ink layer is embedded in the lens body and includes a plurality of color ink membrane thicknesses. The color ink membrane thicknesses are different from each other. The color ink layer includes a plurality of color ink elements, and the color ink elements include M types of areas, in which M is a natural number greater than one. The color ink layer further includes color ink membrane thicknesses from a first color ink membrane thickness to a (1+n)-th color ink membrane thickness, in which n is a natural number greater than zero. These color ink membrane thicknesses and the M types of areas form M*(1+n) units of color ink concentration, and the M*(1+n) units of color ink concentration forms a multicolor pattern in the lens body.

Abstract: The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be kinase (e.g., HCK, BTK, LYN, BLK, FRK) inhibitors. Also provided are pharmaceutical compositions and kits including the provided compounds. Further provided are methods of using the provided compounds, pharmaceutical compositions, and kits (e.g., for treating diseases (e.g., proliferative diseases) in a subject in need thereof).

Abstract: Embodiments of this application provide a battery equalization method and device, and a battery management system. The method includes: obtaining a first closed circuit voltage of N cells in a duration of a pulse charge current and a second closed circuit voltage of the N cells in a duration of a pulse discharge current, where the N cells constitute a battery, and N is a positive integer; determining a relationship of SOC values between the N cells based on the first closed circuit voltage and the second closed circuit voltage; and performing charge equalization on target cells, where the target cells are determined from the N cells based on the relationship of SOC values.

Abstract: The present application provides a method and apparatus for correcting a state of charge. The method for correcting a state of charge comprises: determining an operating state of a battery cell, wherein the operating state comprises a discharging state or a charging state; and determining a corrected state of charge of the battery cell according to an acquired current open circuit voltage of the battery cell, an acquired current accumulative capacity of the battery cell, an accumulative capacity correspondence relationship corresponding to the operating state of the battery cell, and an open circuit voltage curve corresponding to a limit initial state of charge, wherein the accumulative capacity correspondence relationship comprises a correspondence relationship between a pre-measured open circuit voltage and an accumulative capacity threshold. A technical solution of the present application can be used to improve the accuracy of calculation of a state of charge.

Abstract: A method for improving a convolutional neural network (CNN) to perform computations is provided. The method includes the following steps: determining a number of a plurality of multipliers to be N and a number of a plurality of adders to be N according to a number of convolution kernels used by a plurality of convolution layers; and in response to an i-th convolutional layer of the convolutional neural network performing a convolution operation and N convolution kernels of the i-th convolutional layer being all in a size of K×1×1, using the N multipliers and the N adders to perform a multiplication operation once and an addition operation once for each of the N convolution kernels of the i-th convolutional layer in one cycle, such that N outputs of the N convolution kernels of the i-th convolutional layer are obtained after K cycles.

Abstract: Provided herein are methods of treating diseases (e.g., proliferative disease (e.g., cancer (e.g., breast cancer, colon cancer, testicular cancer, CNS cancer, stomach cancer, lymphoma (e.g., B-cell lymphoma (e.g., lymphoplasmacytic lymphoma (e.g., IgM secreting lymphoplasmacytic lymphoma (i.e., Waldenstrom's Macroglobulinemia), non-IgM secreting lymphoplasmacytic lymphoma)), diffuse large B-cell lymphoma (e.g., activated B-cell-like (ABC)-DLBCL, germinal center B-cell-like (GBC)-DLBCL), follicular lymphoma, marginal zone B-cell lymphoma, small lymphocytic lymphoma, mantle cell lymphoma), and leukemia (e.g., chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia, myelogenous leukemia (e.g., chronic myelogenous leukemia, acute myelogenous leukemia))))) comprising administering to the subject in need thereof a therapeutically effective amount of Compound (I). Further provided are methods for treating disease resistant to treatment with BTK inhibitors (e.g., ibmtinib).

Abstract: An optimization method for an implementation of mel-frequency cepstral coefficients is provided. The optimization method includes the following steps: performing a framing step, including using a 400×16 static random access memory to temporarily store a plurality of sampling points of a sound signal with overlap, and decomposing the sound signal into a plurality of frames. Each of the plurality of frames is 400 of the sampling points, there is an overlapping region between adjacent two of the plurality of frames, and the overlapping region includes 240 of the sampling points. The optimization method further includes performing a windowing step, which includes multiplying each of the plurality of frames by a window function in a bit-level design, and the optimization method includes performing a fast Fourier transform (FFT) step, which includes applying a 512 point FFT on a frame signal to obtain a corresponding frequency spectrum.

Abstract: Provided herein are bifunctional compounds with a moiety (e.g., lenalidomide, thalidomide) that is a binder of an E3 ubiquitin ligase (e.g., Cereblon) and another moiety that is a binder of a kinase (e.g., HCK, BTK) to induce degradation of the kinase (e.g., HCK, BTK). Also provided are pharmaceutical compositions comprising the bifunctional compounds, and methods of treating and/or preventing diseases (e.g., proliferative diseases (e.g., non-Hodgkin's lymphoma, Burkitt's lymphoma, Waldenstrom macroglobulinemia, MYD88-mutated Waldenstrom macroglobulinemia, activated B-cell diffuse large B-cell lymphoma, leukemia)), inflammatory disease, or other diseases associated with MYD88 mutations). Provided also are methods of inducing the degradation of a kinase (e.g., HCK, BTK) in a cell in a biological sample or subject by administering the bifunctional compound or composition described herein.

Abstract: The present invention provides compounds of any one of Formulae (A), (I-11), (II), and (V) (e.g., compounds of Formula (A-1)-(A-18)), and methods for treating Waldenström's macroglobulinemia (WM) and other B cell neoplasm in a subject using the compounds. The methods comprise administering to a subject in need thereof an effective amount of the compounds. Also provided are methods to treat B cell neoplasms using the compounds in combination with inhibitors of Bruton's tyrosine kinase (BTK), interleukin-1 receptor-associated kinase 1 (IRAK1), interleukin-1 receptor-associated kinase 4 (IRAK4), bone marrow on X chromosome kinase (BMX), phosphoinositide 3-kinase (PI3K), transforming growth factor b-activated kinase-1 (TAK1), and/or a Src family kinase.